Early effects of parathyroidectomy on erythropoietin production in secondary hyperparathyroidism

被引:47
作者
Yasunaga, C [1 ]
Matsuo, K [1 ]
Yanagida, T [1 ]
Matsuo, S [1 ]
Nakamoto, M [1 ]
Goya, T [1 ]
机构
[1] Saiseikaik Yahata Hosp, Kidney Ctr, Higashi Ku, Kitakyushu, Fukuoka 8050050, Japan
关键词
erythropoietin resistance; renal anemia; uremic toxin; nutrition;
D O I
10.1016/S0002-9610(01)00865-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Secondary hyperparathyroidism (2-HPT) has an adverse effect on renal anemia and may cause a hyporesponsiveness to recombinant human erythropoietin (rHuEpo) in patients with chronic renal failure. The early effects of parathyroidectomy (PTx) on renal anemia, erythropoietin production, and nutritional state were examined. Methods: Twenty-nine patients under hemodialysis therapy received a PTx for 2-HPT. They were prospectively studied regarding hematological parameters, rHuEpo use, plasma erythropoietin levels, and nutritional condition until 12 months after PTx. Results: The hemoglobin level showed a significant increase from 3 months after PTx (10.2% +/- 1.5% to 11.2% +/- 1.3%; P <0.01), associated with a consistent increase of the reticulocyte count. These changes lasted until 12 months after PTx. The plasma erythropoietin level showed a gradual increase of up to about 5 times the level of the preoperative value, until 12 months after PTx (22.6 +/- 10.1 to 106.3 +/- 112.1 mU/mL; P < 0.001). The weekly dose of rHuEpo administration decreased after 3 months. The serum levels of albumin and total protein also significantly and gradually improved until 12 months after PTx. Conclusions: PTx caused a significant early improvement in renal anemia in patients with secondary hyperparathyroidism. This effect may be caused by an enhanced erythropoietin production and may also be partially due to the improved nutritional state after PTx. (C) 2002 Excerpta Medica, Inc. All rights reserved.
引用
收藏
页码:199 / 204
页数:6
相关论文
共 34 条
[1]
GASTRIC-ACID SECRETION, CALCITONIN AND SECONDARY HYPER-PARATHYROIDISM IN UREMIC PATIENTS UNDERGOING REGULAR DIALYSIS THERAPY (RDT) [J].
ANTONUCCI, F ;
VEZZADINI, P ;
CECCHETTIN, M ;
BONORA, G ;
ADAMI, A ;
COMPIANO, U ;
FEDER, G .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1978, 1 (06) :260-265
[2]
HIGH-DOSE ALFACALCIDOL FOR ANEMIA IN DIALYSIS [J].
ARGILES, A ;
LORHO, R ;
MOURAD, G ;
MION, CM .
LANCET, 1993, 342 (8867) :378-379
[3]
EFFECT OF PARATHYROIDECTOMY ON ANEMIA IN CHRONIC RENAL-FAILURE [J].
BARBOUR, GL .
ARCHIVES OF INTERNAL MEDICINE, 1979, 139 (08) :889-891
[4]
BERRIDGE MV, 1988, BLOOD, V72, P970
[5]
BLAND KI, 1985, SURG GYNECOL OBSTET, V160, P42
[6]
BRUNO E, 1989, BLOOD, V73, P671
[7]
RHUEPO HYPORESPONSIVENESS - WHO AND WHY [J].
DANIELSON, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 :69-73
[8]
DRUEKE TB, 1991, AM J KIDNEY DIS, V18, P87
[9]
FRIED W, 1989, MOL BIOL ERYTHROPO, P39
[10]
Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients [J].
Goicoechea, M ;
Vazquez, MI ;
Ruiz, MA ;
Gomez-Campdera, F ;
Perez-Garcia, R ;
Valderrábano, F .
NEPHRON, 1998, 78 (01) :23-27